CNS Summit 2013, Boca Raton, FL Christopher Missling, Tangui Maurice, Athan Spiros, Patrick Roberts and Hugo Geerts View Poster Post navigationPreviousPrevious post:Anavex Appoints Clinical Design Expert to Scientific Advisory BoardNextNext post:Anavex CEO Invited to Present at Upcoming Investment ConferencesRelated PostsAnavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s DiseaseJune 4, 2020Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)May 21, 2020 Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business UpdatesMay 7, 2020Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020May 5, 2020
Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s DiseaseJune 4, 2020
Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)May 21, 2020
Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business UpdatesMay 7, 2020
Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020May 5, 2020
